$RARE

Ultragenyx Pharmaceutical (RARE) announced that the European Medicines Agency (EMA) has validated its Marketing Authorisation Application for rebisufligene etisparvovec, a gene therapy for Sanfilippo syndrome Type A. This validation confirms the filing is complete for review but does not guarantee approval. The company reported a US$115 million loss in Q2 2025 and has a cash runway of less than one year.

FuelCell Energy (FCEL) shares dropped 15% after announcing a CFO transition. Ondas (ONDS) fell 5% despite $165M in new orders. Ultragenyx (RARE) rose 3.2% after selling a priority review voucher for $210M. TNR Gold (TNR) received an acquisition proposal from Altius (ALS). Rocket Pharma (RCKT) gained 4% after securing a $150M credit facility. Sigma Lithium (SGML) resumed operations after court approval. Hess Midstream (HESM) fell 16% after Chevron deal.

Ultragenyx Pharmaceutical Inc. (RARE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 6, 2026, Ultragenyx Pharmaceutical Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Asset Purchase Agreement”), pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority R

Ultragenyx Pharmaceutical (RARE) agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210M. The voucher was received after FDA approval of GENGLYCOS, a treatment for glycogen storage disease type Ia. The deal, subject to closing conditions, will provide non-dilutive capital to advance rare disease therapies and support profitability. Jefferies LLC and Gibson Dunn are advising Ultragenyx.

Ultragenyx announced the EMA validated its MAA for UX111, a gene therapy for MPS IIIA, allowing formal review. This follows prior U.S. approval and may lead to EU market access if approved.

Ultragenyx submitted a Marketing Authorisation Application (MAA) to the EMA for its gene therapy rebisufligene etisparvovec, targeting MPS IIIA (Sanfilippo syndrome Type A). The EMA validated the application, initiating a formal review. The therapy has received PRIME and Orphan Drug Designations. Ultragenyx aims to expand regulatory discussions globally. MPS IIIA is a rare, fatal disorder with limited treatment options.

Ultragenyx Pharmaceutical (RARE) received FDA approval for FAYUVI, a gene therapy for Sanfilippo syndrome Type A. This is the first treatment for this rare disease and includes a Priority Review Voucher. The approval validates Ultragenyx's capabilities and addresses prior regulatory concerns. Analysts forecast earnings of $43.8M by 2029, assuming revenue growth to $1.2B, but risks include high cash burn and potential dilution.

Ultragenyx Pharmaceutical (RARE) shares rose 9% this week after FDA approved Fayuvi, a gene therapy for Sanfilipso syndrome, and raised price targets. The stock rebounded from a 44% drop after its Angelman syndrome trial failed. Analysts see value in its $1.4B market cap and new therapies. RARE plans to sell priority review vouchers for ~$400M.

Ultragenyx (RARE) received FDA approval for Fayuvi, a treatment for Sanfilippo syndrome Type A, causing a 12% stock jump. The company aims for profitability by 2027, with Fayuvi expected to contribute significantly to revenue. Fayuvi is priced at $3.95 million per treatment, with estimated peak sales of $200M-$250M. Hedge funds and short interest activity increased before the approval.

Analysts from Barclays and Bank of America updated ratings for healthcare companies. Helus Pharma (HELP) and Ultragenyx Pharmaceutical (RARE) both received Buy ratings with $35 price targets. Novavax (NVAX) was rated Sell with a $7 target. Current prices and analyst consensus targets were also provided.